Table 1.

Summary of patient data.

			Receptor status
Patients	Age (yr)	Treatment regimens	ER	PR	HER2	Tumor grade	Pathologic response	Excised tumor size (cm)
1	36	AC → taxol	+	+	+	2	Residual disease	1
2	48	Taxotere + carboplatin + herceptin	−	−	+	3	pCR	0
3	58	Cisplatin + taxol ± everolimus	−	+	−	2	Residual disease	1.7
4	33	AC → taxol	+	+	−	3	Residual disease	1.2
5	39	AC → taxol	−	−	−	3	pCR	0
6	43	Cisplatin + taxol ± everolimus	−	−	+	3	Residual disease	0.7
7	57	AC → taxol	−	−	−	3	Residual disease	N/A
8	55	AC → taxol	+	+	−	2	Residual disease	3.5
9	46	Taxotere + carboplatin + herceptin	+	+	+	3	Residual disease	0.3
10	39	AC → taxol	+	+	−	1	Residual disease	2.5